Last updated
Tesamorelin and CJC-1295 are both GHRH-receptor agonists that prompt the pituitary to release the body’s own growth hormone. One is an FDA-approved drug with a specific indication and Phase 3 evidence; the other is a research compound built on a shorter GHRH fragment. That difference — approved-and-characterized versus research-grade — is the real story.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | Stabilized GHRH(1-44) analog | Modified GHRH(1-29) analog (Mod GRF 1-29) |
| Receptor | GHRH receptor (GHRHR) | GHRH receptor (GHRHR) |
| Key modification | N-terminal trans-3-hexenoic acid on full-length GHRH(1-44) | Four DPP-4-resistant substitutions ± albumin-binding DAC |
| Duration / dosing | Short-acting — dosed daily (SC) | No DAC: ~30 min pulse · with DAC: ~6–8 days |
| GH release pattern | Prompts endogenous, feedback-preserving GH | Pulsatile (no DAC) / sustained, blunted pulse (DAC) |
| Approval status | FDA approved (Egrifta, 2010) | None — research compound |
| Approved indication | Excess visceral fat in HIV-associated lipodystrophy | — |
| Evidence base | Completed Phase 3 trials | Human PK plus preclinical / anecdotal |
| Molecular weight | 5135.9 Da | ~3.6 kDa (with DAC) |
| Commonly paired with | Studied as monotherapy (approved) | A GHRP (e.g. ipamorelin) |
Tesamorelin is a stabilized analog of the full 44-residue GHRH sequence, capped at the N-terminus with a trans-3-hexenoic acid group that protects it from rapid breakdown. It is short-acting and dosed daily — but it is the only GHRH analog to carry an FDA approval, granted in 2010 (Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, backed by completed Phase 3 trials. Because it stimulates the pituitary to release endogenous GH, it preserves more of the body’s natural feedback than exogenous GH would.
CJC-1295 starts from a shorter piece — the first 29 residues of GHRH — with four substitutions that resist DPP-4. On its own (no DAC) it produces a brief, ~30-minute pulse; with the Drug Affinity Complex, it binds albumin and stretches to a 6–8-day half-life, trading pulsatility for sustained elevation. It is a research compound: its human evidence is largely pharmacokinetic, and it is typically studied alongside a GHRP rather than as a standalone therapy. So beyond the shared receptor, the two diverge on the thing that matters most for a reference — the depth and grade of the evidence behind them.
Both raise endogenous GH through the GHRH receptor, but they sit on opposite sides of the evidence line. Tesamorelin is an approved drug with a defined indication, a known structure, and Phase 3 data — the reference point for what a characterized GHRH analog looks like. CJC-1295 is a research compound on a truncated backbone whose main appeal is the multi-day duration the DAC provides; its evidence is thinner and it is not approved. For research framing, tesamorelin is the benchmark and CJC-1295 the experimental tool.
Both are GHRH-receptor agonists that stimulate the pituitary to release growth hormone. Tesamorelin is a stabilized full-length GHRH(1-44) analog and the only FDA-approved GHRH analog (Egrifta, for HIV-associated visceral fat). CJC-1295 is a modified GHRH(1-29) research compound that, with a Drug Affinity Complex (DAC), can last 6–8 days.
Yes — as Egrifta (2010), to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. CJC-1295 is not FDA-approved for any use.
CJC-1295 with DAC lasts far longer (6–8 days) than tesamorelin, which is short-acting and dosed daily. Longer duration is not automatically better: sustained GHRH exposure blunts the natural pulsatility of the GH axis, whereas tesamorelin’s daily dosing better preserves it.
GHRH analogs and GHRPs (like ipamorelin) act on different receptors on the same pituitary cells; combining them is studied for synergistic GH release. Tesamorelin, as an approved drug, is used as monotherapy in its indication. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between Tesamorelin and CJC-1295 — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.